Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.

There is evidence to suggest that CDC25B phosphatase is an oncogenic protein. To elucidate the role of CDC25B in colorectal carcinoma, we examined the expression of CDC25B at the mRNA and protein levels. Reverse transcription-PCR assay indicated that CDC25B was overexpressed in tumor tissues relative to normal mucosa in 6 of 10 cases. Using immunohistochemistry, we identified high expression of CDC25B in 77 of 181 colorectal cases (43%). Univariate analysis showed that high expression was a significant predictor for poor prognosis compared with low expression (5-year survival rate; 59% versus 82%, respectively; P < 0.0001). Multivariate analysis indicated that CDC25B was an independent prognostic marker (risk ratio for death, 3.7; P < 0.0001) even after controlling for various factors such as lymph node metastasis, tumor size, degree of differentiation, and depth of invasion. Furthermore, the level of CDC25B expression clearly predicted the outcome of patients with Dukes' B and Dukes' C tumors. On the other hand, CDC25A mRNA was overexpressed in 9 of 10 colorectal cancer cases, and immunohistochemistry for CDC25A showed high expression in 52 of 111 cases (47%), but no significant correlation with prognosis. Our findings suggest that CDC25B is a novel independent prognostic marker of colorectal carcinoma and that it may be clinically useful for selecting patients who could benefit from adjuvant therapy.

[1]  H. McLeod,et al.  Tumour markers of prognosis in colorectal cancer , 1999, British Journal of Cancer.

[2]  P. gordon,et al.  Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67 , 1997, Diseases of the colon and rectum.

[3]  F. A. Coller,et al.  THE PROGNOSTIC SIGNIFICANCE OF DIRECT EXTENSION OF CARCINOMA OF THE COLON AND RECTUM , 1954, Annals of surgery.

[4]  T. Hunter,et al.  Cyclins and cancer , 1991, Cell.

[5]  T. Moyana,et al.  Elevated expression of the cdc25A protein phosphatase in colon cancer. , 1998, Experimental cell research.

[6]  H. Hibshoosh,et al.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.

[7]  Xiao-Feng Sun,et al.  Ki‐67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  R. Poulsom,et al.  Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. , 1995, British Journal of Cancer.

[9]  山本 浩文.  Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer , 1995 .

[10]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[11]  E. Campo,et al.  cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas. , 1998, Cancer Research.

[12]  M. Leader,et al.  Cytoplasmic c‐erbB‐2 protein expression correlates with survival in Dukes' B colorectal carcinoma , 1994, Histopathology.

[13]  R. Gafà,et al.  Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma , 1998, Cancer.

[14]  R. DuBois,et al.  Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. , 1997, Cancer research.

[15]  H. Yokozaki,et al.  Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas , 1995, International journal of cancer.

[16]  I. Hoffmann,et al.  Ectopic Expression of Cdc25A Accelerates the G1/S Transition and Leads to Premature Activation of Cyclin E- and Cyclin A-Dependent Kinases , 1999, Molecular and Cellular Biology.

[17]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[18]  S. Sakiyama,et al.  Reduced messenger RNA expression level of p21CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation , 1996, International journal of cancer.

[19]  E. Karsenti,et al.  Activation of the phosphatase activity of human cdc25A by a cdk2‐cyclin E dependent phosphorylation at the G1/S transition. , 1994, The EMBO journal.

[20]  Y. Doki,et al.  Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Schulte‐Mönting,et al.  Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.

[22]  R. Maestro,et al.  Overexpression of CDC25A and CDC25B in head and neck cancers. , 1997, Cancer research.

[23]  C. V. D. van de Velde,et al.  Micrometastases and survival in stage II colorectal cancer. , 1998, The New England journal of medicine.

[24]  W. Ansorge,et al.  The cdc25B phosphatase is essential for the G2/M phase transition in human cells. , 1998, Journal of cell science.

[25]  I. Schieren,et al.  Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells , 1999, Oncogene.

[26]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[27]  H. Hibshoosh,et al.  Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice , 1999, Oncogene.

[28]  P. Romeo,et al.  Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Mason,et al.  Ki‐67 immunostaining and survival in operable lung cancer , 1991, Histopathology.

[30]  M. Monden,et al.  Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  D. Huhn,et al.  Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). , 1996, Nucleic acids research.

[32]  A Nagata,et al.  An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. , 1991, The New biologist.

[33]  T. Bauer,et al.  Ki‐67‐determined growth fraction versus standard staging and grading parameters in colorectal carcinoma: A multivariate analysis , 1992, Cancer.

[34]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[35]  N. Hayward,et al.  Multiple splicing variants of cdc25B regulate G2/M progression. , 1999, Biochemical and biophysical research communications.

[36]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[37]  P. Russell,et al.  Fission yeast p107wee1 mitotic inhibitor is a tyrosine/serine kinase , 1991, Nature.

[38]  F. Sinicrope,et al.  Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  K. Sadhu,et al.  Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Tsai,et al.  Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B , 1999, Oncogene.

[41]  Charles J. Sherr,et al.  Mammalian G1 cyclins , 1993, Cell.

[42]  Ingrid Hoffmann,et al.  Cdc25b and Cdc25c Differ Markedly in Their Properties as Initiators of Mitosis , 1999, The Journal of cell biology.

[43]  D. Beach,et al.  Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins , 1991, Cell.

[44]  Jeng-Jong Hwang,et al.  Ki‐67 expression as a prognostic marker in patients with hepatocellular carcinoma , 1998, Journal of gastroenterology and hepatology.

[45]  H. Piwnica-Worms,et al.  p107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  N. Hayward,et al.  Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. , 1996, Journal of cell science.

[47]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[48]  H. Yokozaki,et al.  Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas , 1993, International journal of cancer.

[49]  G. Cattoretti,et al.  Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. , 1998, Cancer research.

[50]  M. Loda,et al.  CDC25 phosphatases as potential human oncogenes. , 1995, Science.

[51]  L. Ellis,et al.  Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. , 1997, Archives of surgery.

[52]  M. Duffy,et al.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.

[53]  L. Mao,et al.  Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. , 1998, Cancer research.

[54]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.